Jardiance

(Empagliflozin)

ApprovedSmall molecule

Empagliflozin is used to treat type 2 diabetes by helping the kidneys remove excess sugar through urine, and it also helps protect the heart and kidneys in patients with diabetes or heart disease.[2] Jardiance is currently approved and in use across 86 indications[4].[1]

Jardiance is one of 1494 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

399

Total Trials

Active Trials

1,493

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Insulin ResistanceActive, not recruiting

Coronary Artery DiseaseActive, not recruiting

Metabolic SyndromeActive, not recruiting

Glycogen Storage Disease Due to Glucose-6-Phosphatase Deficiency Type IAApproved

Hepatic FailureApproved

AscitesActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Endothelial DysfunctionActive, not recruiting

Chronic PancreatitisActive, not recruiting

Diabetic KetoacidosisActive, not recruiting

Insulin ResistancePhase 3

Active, not recruiting

Coronary Artery DiseaseApproved

Active, not recruiting

Metabolic SyndromePhase 3

Active, not recruiting

Glycogen Storage Disease Due to Glucose-6-Phosphatase Deficiency Type IAApproved

Approved

Hepatic FailureApproved

Approved

AscitesPhase 2

Active, not recruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

Endothelial DysfunctionApproved

Active, not recruiting

Chronic PancreatitisPhase 2

Active, not recruiting

Diabetic KetoacidosisPreclinical

Active, not recruiting

Showing 10 of 85 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Approved

2 2

Trodelvy

Gilead

Preclinical

37 3

Lexiscan

Astellas

Preclinical

1 4

Adenocard

Astellas

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 9

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 10

Lapatinib Plus Capecitabine

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/AActive, not recruiting

Type 2 Diabetes

NCT05313529

Phase 3Recruiting

Heart Failure

NCT06024746

Phase 2/3Active, not recruiting

Nephrotic Syndrome

NCT07214818

Q4 2026

Phase 2Recruiting

Kidney Disease

NCT05638880

Phase 3Active, not recruiting

Hypertrophic Cardiomyopathy

NCT05182658

Phase 1Recruiting

Pulmonary Arterial Hypertension

NCT06554301

Clinical

Trials by Indication[1]

Empagliflozin49 trials

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Completed·—·Phase 3·NCT05036421·18 enrolled

Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

Unknown status·—··NCT06284850·40 enrolled

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02106923·72 enrolled

Show 46 more trials

Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

Unknown status·BBio-innova Co., Ltd·Phase 1·NCT06232239·26 enrolled

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07213895·14 enrolled

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT05132023·26 enrolled

Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01672788·36 enrolled

A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05083949·32 enrolled

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01811953·48 enrolled

Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions

Completed·MMutah University·N/A·NCT05229796·26 enrolled

Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07266766·40 enrolled

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Completed·GGedeon Richter Plc.·Phase 1·NCT06792968·64 enrolled

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Completed·DDong-A ST Co., Ltd.·Phase 1·NCT03766724·42 enrolled

Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT06932159·40 enrolled

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Completed·GGedeon Richter Plc.·Phase 1·NCT06766500·64 enrolled

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Completed·HHandok Inc.·Phase 1·NCT06889350·40 enrolled

Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07372118·32 enrolled

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Completed·GGedeon Richter Plc.·Phase 1·NCT06823856·64 enrolled

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01975220·72 enrolled

Empagliflozin in ESKD - A Feasibility Study

Recruiting·UUniversity of Mississippi Medical Center·Phase 1/2·NCT05687058·24 enrolled

A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With Food

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06962826·14 enrolled

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Unknown status·LLG Chem·Phase 1·NCT03565458·48 enrolled

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02758171·56 enrolled

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02632747·31 enrolled

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04295005·24,500 enrolled

Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

Active, not recruiting·CConrado Roberto Hoffmann Filho·Phase 3·NCT06683053·90 enrolled

Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

Unknown status·SSeoul National University Bundang Hospital·Phase 4·NCT05140694·135 enrolled

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03429543·175 enrolled

Drug Interaction Study Between Dorzagliatin and Empagliflozin

Completed·HHua Medicine Limited·Phase 1·NCT03790787·16 enrolled

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01867307·39 enrolled

Emp-Activity: Empagliflozin Functional Capacity

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05350202·3,431 enrolled

Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT03510000·30 enrolled

Empagliflozin and Sympathetic Nerve Traffic

Completed·PProfil Institut für Stoffwechselforschung GmbH·Phase 4·NCT03254849·75 enrolled

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

Completed·—·Phase 1·NCT06828731·60 enrolled

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)

Completed·UUniversity of Catanzaro·Phase 4·NCT04183868·26 enrolled

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02230995·30 enrolled

Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

Recruiting·GGetz Pharma·Phase 4·NCT05164263·2,000 enrolled

Use of Empagliflozin to Treat Prediabetes

Active, not recruiting·OOregon State University·Phase 4·NCT05426525·60 enrolled

Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics

Completed·JJohannes Gutenberg University Mainz·Phase 4·NCT02932436·144 enrolled

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Completed·HHandok Inc.·Phase 1·NCT04431141·32 enrolled

Empagliflozin in Adolescent Diabetes

Withdrawn·OOhio State University·Phase 4·NCT04917692

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy

Unknown status·—··NCT05103306·300 enrolled

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

Unknown status·JJinnah Postgraduate Medical Centre·Phase 4·NCT05942963·240 enrolled

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02102932·96 enrolled

Effect of Empagliflozin on Ventricular Repolarization.

Completed·UUniversity of Sao Paulo·Phase 4·NCT04117763·90 enrolled

The Effects of Empagliflozin on Arterial Wall Characteristics

Unknown status·UUniversity Medical Centre Ljubljana·Phase 4·NCT03639545·120 enrolled

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.

Completed· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·N/A·NCT03771781·48 enrolled

Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Terminated·IIntarcia Therapeutics·Phase 3·NCT03060980·245 enrolled

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Completed·—·N/A·NCT06313008·120 enrolled

Type 2 Diabetes19 trials

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Completed·MMedanta, The Medicity, India·N/A·NCT02686476·100 enrolled

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01734785·607 enrolled

Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

Completed·IInstitut für Pharmakologie und Präventive Medizin·Phase 3·NCT02752113·101 enrolled

Show 16 more trials

SGLT2i, Pioglitazone, and Ketone Production in T2D

Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT07053319·64 enrolled

Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes

Unknown status·UUnity Health Toronto·Phase 4·NCT02998970·97 enrolled

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

Unknown status·MMetacrine, Inc.·Phase 2·NCT04702490·120 enrolled

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

Completed·RRWTH Aachen University·Phase 2·NCT03132181·40 enrolled

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Withdrawn· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06083675

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT04233801·219 enrolled

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes

Active, not recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·N/A·NCT05313529·396 enrolled

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT04531462·129 enrolled

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

Completed·TThe Deutsche Diabetes Forschungsgesellschaft e.V.·Phase 4·NCT02637973·84 enrolled

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Recruiting·CCelltrion·Phase 3·NCT07093476·171 enrolled

Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01984606

The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes

Unknown status·UUniversity of Malaya·Phase 4·NCT02964715·25 enrolled

Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

Completed·SSINA Health Education and Welfare Trust·Phase 4·NCT06145360·150 enrolled

Mediterranean Diet, Circuit Resistance Training, Empagliflozin in Elderly With Type 2 Diabetes: a Study Protocol

Completed·TTel-Aviv Sourasky Medical Center·Phase 4·NCT03560375·100 enrolled

Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes

Completed·YYonsei University·N/A·NCT02964572·61 enrolled

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

Withdrawn· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05444153

Heart Failure13 trials

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04937816·16,746 enrolled

Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients

Unknown status·RRambam Health Care Campus·Phase 4·NCT03271879·128 enrolled

Comparison of Empagliflozin and Dapagliflozin in Patients With Heart Failure Taking Standard Treatment

Completed·FFatima Maqsood·N/A·NCT06915870·108 enrolled

Show 10 more trials

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

Completed·SSaint Luke's Health System·Phase 4·NCT03030222·65 enrolled

Empagliflozin in Heart Failure Dialysis Patients

Completed·SShahid Beheshti University of Medical Sciences·N/A·NCT05967156·30 enrolled

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03448419·312 enrolled

EMPA Acute Heart Failure

Terminated·RRWTH Aachen University·Phase 2·NCT03554200·19 enrolled

Canagliflozin in Patients With Acute Decompansted Heart Failure

Completed·OOctober 6 University·Phase 3·NCT05364190·142 enrolled

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03057951·5,988 enrolled

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT04157751·530 enrolled

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)

Recruiting·CColorado Prevention Center·Phase 3·NCT06024746·1,500 enrolled

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

Unknown status·—·Phase 2·NCT06012266·12 enrolled

The Cardiac Effects of Empagliflozin in Patients With High Risk of Heart Failure

Completed·JJacob Moller·Phase 2·NCT05084235·191 enrolled

Type 2 Diabetes Mellitus11 trials

Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05130463·1,053 enrolled

Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus

Unknown status·CCentro Universitario de Ciencias de la Salud, Mexico·Phase 3·NCT04195243·24 enrolled

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02182830·166 enrolled

Show 8 more trials

Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus

Completed·—·Phase 3·NCT06952231·50 enrolled

A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)

Not yet recruiting·—·Phase 4·NCT07311551·112 enrolled

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02453555·275 enrolled

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02121483·27 enrolled

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Completed·IInventiva Pharma·Phase 2·NCT05232071·42 enrolled

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Terminated· Novartis logo

Novartis·Phase 2·NCT03152552·125 enrolled

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03249506·25,358 enrolled

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02863328·822 enrolled

Diabetes Mellitus8 trials

Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension

Withdrawn·EEMS·Phase 3·NCT04970108

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Recruiting·EEMS·Phase 3·NCT04670666·270 enrolled

Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions

Completed·RResearch Institute for Complex Problems of Cardiovascular Diseases, Russia·Phase 4·NCT04497792·40 enrolled

Show 5 more trials

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

Recruiting·EEMS·Phase 3·NCT05028140·480 enrolled

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

Completed·GGetz Pharma·Phase 4·NCT04665284·244 enrolled

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

Unknown status·EEMS·Phase 3·NCT04603508·240 enrolled

Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus

Completed·NNational Medical Research Center for Cardiology, Ministry of Health of Russian Federation·Phase 4·NCT03753087·70 enrolled

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus

Recruiting·MMedanta, The Medicity, India·N/A·NCT06095492·200 enrolled

82 more indications

Kidney Transplant3 trials

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

Terminated·—·Phase 2·NCT04906213·20 enrolled

Empagliflozin Treatment in Kidney Transplant Recipients

Recruiting·VVA Office of Research and Development·Phase 4·NCT06013865·264 enrolled

Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

Completed·SShahid Beheshti University of Medical Sciences·N/A·NCT04918407·40 enrolled

Cardiomyopathy2 trials

A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy

Unknown status·HHuashan Hospital·N/A·NCT04520646·10 enrolled

Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age

Not yet recruiting·SSebastiano Lava·Phase 2·NCT06643442·12 enrolled

Trial2 trials

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

Recruiting·UUniversity of Pennsylvania·Phase 2·NCT05138575·53 enrolled

Feasibility Trial for a Right Ventricular Failure Platform Trial

Recruiting·UUniversity of Alberta·Phase 2·NCT06570473·30 enrolled

Myocardial Infarction2 trials

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT04509674·6,522 enrolled

EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction

Active, not recruiting·NNHS Greater Glasgow and Clyde·Phase 3·NCT05020704·100 enrolled

Hyperglycemia2 trials

Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio

Completed·UUniversity of Diyala··NCT05822674·80 enrolled

Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia

Completed·MMedanta, The Medicity, India·N/A·NCT06187285·220 enrolled

Type 1 Diabetes Mellitus2 trials

Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01969747·75 enrolled

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02702011·48 enrolled

Non-Alcoholic Steatohepatitis2 trials

Reducing Non-Alcoholic Steatohepatitis

Enrolling by invitation·MMilitary University Hospital, Prague·N/A·NCT06519448·30 enrolled

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT05282121·90 enrolled

Cardiovascular Disease2 trials

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04927858·460,558 enrolled

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05102071

Neutropenia2 trials

Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

Unknown status·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT04138251·5 enrolled

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05078879·4 enrolled

Chronic Kidney Disease2 trials

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT05182840·714 enrolled

Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease

Unknown status·MMedical University of Lodz·N/A·NCT04961931·45 enrolled

Hypertension2 trials

SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Completed·JJichi Medical University·Phase 4·NCT03050229·174 enrolled

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

Completed· Sanofi logo

Sanofi·Phase 2·NCT03462069·41 enrolled

Type 1 Diabetes2 trials

Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes

Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT06021145·46 enrolled

Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes

Recruiting·MMostafa Bahaa·Phase 2·NCT06762314·105 enrolled

Kidney Disease2 trials

Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease

Unknown status·OOmar Tarek Elfarargi·Phase 2/3·NCT05373004·212 enrolled

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

Recruiting·MMostafa Bahaa·Phase 2·NCT05638880·60 enrolled

Polycystic Ovary Syndrome2 trials

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Unknown status·—·Phase 4·NCT05200793·75 enrolled

Empagliflozin vs Metformin on Metabolic Dysfunction in Polycystic Ovary Syndrome With or Without Comorbidity or Multimorbidity

Completed·SSINA Health Education and Welfare Trust·Phase 2/3·NCT06140108·70 enrolled

Acute Kidney Injury2 trials

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Active, not recruiting·—·Phase 1·NCT05360615·147 enrolled

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

Unknown status·FFayoum University··NCT04853615·800 enrolled

Safety and Efficacy1 trial

" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

Unknown status·IInstituto Nacional de Cardiologia Ignacio Chavez·Phase 2/3·NCT05580510·160 enrolled

Cardiovascular1 trial

Cardiovascular Effects of Empagliflozine

Unknown status·TTel Aviv University·N/A·NCT02918591·10 enrolled

Pulmonary Arterial Hypertension1 trial

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

Recruiting·CChina National Center for Cardiovascular Diseases·Phase 1·NCT06554301·72 enrolled

Cardiac1 trial

Impact of Empaglifozine on Cardiac Ectopic Fat

Completed·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT03118336·56 enrolled

Obesity1 trial

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Recruiting·VVA Office of Research and Development·Phase 2·NCT06745063·50 enrolled

Fasting Conditions1 trial

To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07039890·40 enrolled

T2DM1 trial

Glycemic Variability of Combination Therapies in T2DM

Recruiting·JJW Pharmaceutical·Phase 4·NCT07442006·178 enrolled

Mitral regurgitation1 trial

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

Recruiting·RRehab Werida··NCT07379788·180 enrolled

Completed·UUniversity Hospital, Basel, Switzerland·Phase 2/3·NCT02729766·15 enrolled

Inflammation1 trial

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.

Completed·UUniversity of Pisa··NCT04735042·60 enrolled

Congestive Heart Failure1 trial

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

Unknown status·UUniversity Health Network, Toronto·Phase 2·NCT04535960·36 enrolled

MPA1 trial

Empa/Lina FDC Food Effect Study (Japan)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02815644·22 enrolled

Rheumatoid Arthritis1 trial

The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate

Not yet recruiting·TTanta University·Phase 4·NCT06641128·44 enrolled

Nephrotic Syndrome1 trial

SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome

Active, not recruiting·MMansoura University·Phase 2/3·NCT07214818·75 enrolled

Hypoglycemia1 trial

Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes

Withdrawn·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT05174507

SGLT-2 Inhibitor1 trial

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.

Completed·UUniversity of Leicester·Phase 4·NCT02798744·68 enrolled

Fatty Liver1 trial

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

Unknown status·GGetz Pharma·Phase 4·NCT04976283·123 enrolled

Diabetic Ketoacidosis1 trial

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02864914·333,580 enrolled

Microvascular Circulation1 trial

Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT02471963·74 enrolled

Major Depressive Disorder1 trial

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)

Recruiting·NNYU Langone Health·Phase 2·NCT05757791·16 enrolled

Cystic Fibrosis1 trial

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Active, not recruiting·UUniversity of Minnesota·Phase 2/3·NCT06149793·8 enrolled

T1DM1 trial

Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting

Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·Phase 3·NCT03979352·28 enrolled

Diabetes1 trial

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

Completed·—··NCT04215536·103,752 enrolled

Autosomal Dominant Polycystic Kidney Disease1 trial

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT05510115·50 enrolled

Treatment1 trial

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03807440·4,083 enrolled

Albuminuria1 trial

Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

Withdrawn·SSteno Diabetes Center Copenhagen·Phase 4·NCT03504566

Cardiotoxicity1 trial

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT06844669·7 enrolled

Atrial Fibrillation1 trial

Empagliflozin and Atrial Fibrillation Treatment

Unknown status·—·Phase 4·NCT04583813·400 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease

Not yet recruiting·—·Phase 4·NCT07180745·400 enrolled

Antithrombotic1 trial

Antithrombotic Activities of Sotagliflozin vs. Empagliflozin

Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT06618976·17 enrolled

Advanced1 trial

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Withdrawn·NNorthwell Health·Phase 4·NCT02768220

COVID-191 trial

Randomised Evaluation of COVID-19 Therapy

Recruiting·UUniversity of Oxford·Phase 3·NCT04381936·70,000 enrolled

Adiposity1 trial

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT02833415·40 enrolled

Interaction1 trial

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Completed·CChipscreen Biosciences, Ltd.·Phase 1·NCT05681273·48 enrolled

Heart Disease1 trial

SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

Completed·VVanderbilt University Medical Center·Phase 1/2·NCT04907214·29 enrolled

Chronic Hepatitis1 trial

Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients

Active, not recruiting·TThe University of Hong Kong·Phase 4·NCT05147090·106 enrolled

Injury1 trial

Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI

Unknown status·—·N/A·NCT03591991·128 enrolled

Breast Cancer1 trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Recruiting· Roche logo

Roche·Phase 1/2·NCT03424005·792 enrolled

Medication1 trial

Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

Completed·NNational and Kapodistrian University of Athens··NCT05946148·78 enrolled

High Cardiovascular Risk1 trial

SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk

Completed·CCaroline M Kistorp·Phase 3·NCT03151343·92 enrolled

Malignancies1 trial

Empa PASS on Urinary Tract Malignancies

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03464045·344,995 enrolled

Transthyretin Amyloid Cardiomyopathy1 trial

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

Completed·—·Phase 4·NCT05233163·15 enrolled

Oxidative Stress1 trial

The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes

Completed·HHenrik Enghusen Poulsen·Phase 2·NCT02890745·31 enrolled

Ulcerative Colitis1 trial

Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis

Recruiting·TTanta University·Phase 1·NCT05610956·60 enrolled

Urinary Tract Infection1 trial

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03764631·1,502 enrolled

Drug1 trial

Cognitive Protective Effect of Newer Antidiabetic Drugs

Unknown status·—··NCT05347459·100 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT05960617·10 enrolled

Aortic Valve Replacement1 trial

EMPagliflozin After Aortic Valve Replacement

Active, not recruiting·RRigshospitalet, Denmark·Phase 4·NCT06171802·205 enrolled

Elderly1 trial

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

Unknown status·CCenter for Outcomes Research and Clinical Epidemiology, Italy·Phase 4·NCT04796428·1,167 enrolled

MODY1 trial

Impact of SGLT2 on Glucosuria in HNF1A-MODY

Completed·SSteno Diabetes Center Copenhagen·N/A·NCT05417646·21 enrolled

Diabetic Macular Edema1 trial

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

Terminated·HHannover Medical School·Phase 4·NCT02985242·6 enrolled

Chronic Pancreatitis1 trial

Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus

Recruiting·MMayo Clinic·Phase 2·NCT06729996·40 enrolled

Acute Myocardial Infarction1 trial

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Completed·MMedical University of Graz·Phase 3·NCT03087773·476 enrolled

Hypertrophic Cardiomyopathy1 trial

Empagliflozin in Hypertrophic Cardiomyopathy

Active, not recruiting·NNational Institute of Cardiology, Warsaw, Poland·Phase 3·NCT05182658·250 enrolled

Metabolic Syndrome1 trial

Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor

Enrolling by invitation·TThe University of Hong Kong·Phase 3·NCT07065357·160 enrolled

Post-Operative Atrial Fibrillation1 trial

Empagliflozin to Prevent Post-Operative Atrial Fibrillation

Unknown status·RRajaie Cardiovascular Medical and Research Center·Phase 3·NCT06124937·492 enrolled

Glomerulonephritis1 trial

Empagliflozin in Patients With Glomerulonephritis

Completed·KKasr El Aini Hospital·Phase 3·NCT05283057·50 enrolled

NAFLD1 trial

Follow-up of NAFLD Patients With MRI-PDFF

Completed·AAsmaa Abdelfattah Elsayed·Phase 4·NCT04910178·80 enrolled

Cardiorenal Syndrome Type 11 trial

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Recruiting·—·Phase 2/3·NCT06030843·200 enrolled

Mortality1 trial

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

Recruiting·—·Phase 3·NCT05879276·164 enrolled

Peritoneal Dialysis1 trial

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Recruiting·UUniversity Health Network, Toronto·Phase 3·NCT05715814·20 enrolled

Diabetic Neuropathy1 trial

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

Completed·TTanta University·Phase 1/2·NCT05977465·50 enrolled

Liver Disease1 trial

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

Recruiting·JJustin Ryder·Phase 2·NCT06355310·40 enrolled

SGLT2 Inhibitors1 trial

SGLT2 Inhibitors in Glomerular Hyperfiltration

Withdrawn· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT04143581

Unspecified3 trials

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT02792400·24 enrolled

SGLT2 Inhibition and Left Ventricular Mass

Terminated·HHannover Medical School·Phase 4·NCT02728453·7 enrolled

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Completed·—·N/A·NCT06065280·80 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 1, 2014

JARDIANCE

NDA NDA204629

Sources

References

[1]
ClinicalTrials.gov — 399 trial records for Empagliflozin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Jardiance drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Empagliflozin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Empagliflozin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA204629). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Jardiance. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Sodium/glucose Cotransporter 2 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

Patent Landscape[6]

Patent Cliff

Oct 15, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7713938*PEDOct 15, 2027

7579449*PEDFeb 1, 2029

12115179Feb 11, 2030

8551957*PEDApr 14, 2030

12115179*PEDAug 11, 2030

11 more patents

12527810*PEDOct 22, 2033

11813275Apr 3, 2034

12263153Apr 3, 2034

9949997May 17, 2034

11833166*PEDOct 3, 2034

10258637*PEDOct 3, 2034

11813275*PEDOct 3, 2034

11090323*PEDOct 3, 2034

12433906*PEDOct 3, 2034

9949997*PEDNov 17, 2034

9949998*PEDDec 11, 2034

Jardiance

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Empagliflozin49 trials

Type 2 Diabetes19 trials

Heart Failure13 trials

Type 2 Diabetes Mellitus11 trials

Diabetes Mellitus8 trials

Kidney Transplant3 trials

Cardiomyopathy2 trials

Trial2 trials

Myocardial Infarction2 trials

Hyperglycemia2 trials

Type 1 Diabetes Mellitus2 trials

Non-Alcoholic Steatohepatitis2 trials

Cardiovascular Disease2 trials

Neutropenia2 trials

Chronic Kidney Disease2 trials

Hypertension2 trials

Type 1 Diabetes2 trials

Kidney Disease2 trials

Polycystic Ovary Syndrome2 trials

Acute Kidney Injury2 trials

Safety and Efficacy1 trial

Cardiovascular1 trial

Pulmonary Arterial Hypertension1 trial

Cardiac1 trial

Obesity1 trial

Fasting Conditions1 trial

T2DM1 trial

Mitral regurgitation1 trial

Cirrhosis1 trial

Weight loss1 trial

Hyponatremia1 trial

Inflammation1 trial

Congestive Heart Failure1 trial

MPA1 trial

Rheumatoid Arthritis1 trial

Nephrotic Syndrome1 trial

Hypoglycemia1 trial

SGLT-2 Inhibitor1 trial

Fatty Liver1 trial

Diabetic Ketoacidosis1 trial

Microvascular Circulation1 trial

Major Depressive Disorder1 trial

Cystic Fibrosis1 trial

T1DM1 trial

Diabetes1 trial

Autosomal Dominant Polycystic Kidney Disease1 trial

Treatment1 trial

Albuminuria1 trial

Cardiotoxicity1 trial

Atrial Fibrillation1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Antithrombotic1 trial

Advanced1 trial

COVID-191 trial

Adiposity1 trial

Interaction1 trial

Heart Disease1 trial

Chronic Hepatitis1 trial

Injury1 trial

Breast Cancer1 trial

Medication1 trial

High Cardiovascular Risk1 trial

Malignancies1 trial

Transthyretin Amyloid Cardiomyopathy1 trial

Oxidative Stress1 trial

Ulcerative Colitis1 trial

Urinary Tract Infection1 trial

Drug1 trial

Efficacy and Safety1 trial

Aortic Valve Replacement1 trial

Elderly1 trial

MODY1 trial

Diabetic Macular Edema1 trial